<DOC>
	<DOCNO>NCT00084240</DOCNO>
	<brief_summary>The primary objective confirm hypothesis azithromycin ( optimal dose daily three day ) plus chloroquine non-inferior sulfadoxine-pyrimethamine plus chloroquine treatment uncomplicated , symptomatic malaria due P. falciparum .</brief_summary>
	<brief_title>Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated , Symptomatic Falciparum Malaria In Southeast Asia</brief_title>
	<detailed_description>The trial terminate prematurely 2 June 2005 due inability recruit plan number subject . There safety efficacy concern regard study decision terminate trial .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<criteria>Females male &gt; =18 year age uncomplicated , symptomatic malaria indicate presence following : . ) Blood smear positive Plasmodium falciparum asexual parasitemia 1000 100,000 parasites/mL b . ) Fever history fever ( &gt; = 38.5 C/101.2 F rectal tympanic ; &gt; = 37.5 C/99.5 F axillary &gt; = 38 C/100.4 F oral ) within prior 24 hour Serum glucose &gt; = 60 mg/dL ( fingerstick peripheral blood collection ) Positive rapid diagnostic test ( Binax NOW ICT ) P. falciparum Women childbearing potential must negative urine gonadotropin prior entry study must agree use adequate contraception entire study Severe complicate malaria include subject follow : . ) Impaired consciousness , seizures abnormal neurologic exam b . ) Jaundice c. ) Respiratory distress d. ) Persistent vomit e. ) Hematuria , report patient f. ) Parasite density &gt; 100,000 parasites/mL g. ) Presence nonfalciparum specie microscopy Pregnant breastfeeding woman History allergy hypersensitivity azithromycin macrolide , sulfonamide , pyrimethamine , chloroquine Known history blood dyscrasia ( e.g. , megaloblastic anemia , agranulocytosis , aplastic anemia , thrombocytopenia , leukopenia , neutropenia , hemolytic anemia ) History epilepsy psoriasis History treatment antimalarial drug ( chloroquine , quinine , mefloquine , Malarone , SP , artemisinin compound ) antibacterial know antimalarial activity ( macrolides , doxycycline , clindamycin ) within 2 week prior enrollment study Known suspect cardiovascular , hepatic renal abnormality opinion Investigator would place subject increase risk participate study . The following finding specific exclusion : . ) serum creatinine &gt; 2.0 x ULN b . ) ALT and/or AST &gt; 3 x ULN Inability swallow oral medication tablet form Treatment investigational drug within 30 Days prior enrollment study Alcohol and/or drug abuse Requirement use medication study might interfere evaluation study drug ( nelfinavir , digoxin , ergot alkaloid , terfenadine , cyclosporine , hexobarbital phenytoin ) Specific systemic disease medical condition would interfere evaluation therapeutic response safety study drug Inability comprehend and/or unwillingness follow study protocol Intentions leave vicinity trial site next 42 day Prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>